CGTN
8.3.2021 20:08:11 CET | Business Wire | Press release
China is mulling improving the electoral system of the Hong Kong Special Administrative Region (HKSAR) – but critics say it's a plan to eliminate opposition forces in the city.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210308005793/en/
Why are improvements imperative?
When explaining the draft decision on improving the electoral system of the HKSAR to lawmakers, Wang Chen, vice chairman of the National People's Congress (NPC) Standing Committee, said the move is to prevent anti-China, destabilizing forces from seizing power, citing the months-long riots in 2019.
"To remedy the situation, it is important to take necessary steps to improve the electoral system and remove existing institutional deficiencies and risks to ensure the administration of Hong Kong by Hong Kong people with patriots as the main body," Wang said.
Alex Fan, founding president of the International Youth Legal Exchange Federation in Hong Kong, told CGTN that "allowing non-patriots or even people endangering national security to participate in the election will put the 'One Country, Two Systems' in peril."
What can be improved?
According to the draft decision, the focus of the improvements will be on the reform and greater empowerment of the city's Election Committee.
"Hong Kong's chief executive will continue to be elected by the Election Committee. The committee will also elect a relatively large share of Legislative Council (LegCo) members and directly participate in the nomination of all LegCo candidates," Wang said, adding that the revisions to be made may be limited to Annex I and Annex II to the Basic Law, without revising the main body of the Basic Law.
How will it be carried out?
A two-step approach, namely, "decision plus amendment," has been put forward. The NPC, China's top legislature, first makes a decision on improving the electoral system of the HKSAR and authorizes its Standing Committee to amend. Then the NPC Standing Committee amends the Annex I and Annex II to the Basic Law of the HKSAR.
After the amendment at the state level is completed, the HKSAR will amend relevant local laws accordingly.
In consideration of the complexity of Hong Kong's election-related local laws, experts believe the process will take some time but will be completed before elections in Hong Kong in the second half of the year.
What would the improvements mean?
Li Huan, an associate research fellow at the Hong Kong and Macao Research Center, rejected concerns that the non-establishment camp in Hong Kong would have no room to participate in politics after the amendment, saying the decision "does not aim to serve the pro-establishment camp or to restrict the non-establishment camp."
"It depends on how one understands the non-establishment camp. People from the non-establishment camp are not necessarily unpatriotic or those who don't love Hong Kong," Li told CGTN.
This echoed the words of Xia Baolong, vice chairman of the National Committee of the Chinese People's Political Consultative Conference and head of the Hong Kong and Macao Affairs Office of the State Council, who has said the emphasis on "patriots governing Hong Kong" is not meant to erase all differences.
Liu Zhaojia, the vice chairman of the National Hong Kong and Macao Research Association, added: "Pro-establishment candidates can also rest easy. They must put in real efforts to solve Hong Kong's social and livelihood problems in order to gain a better political future."
The Liaison Office of the HKSAR voiced support for improving the electoral system, stating "it is the only way for Hong Kong society to end political disputes, refocus on development and protect the long-term prosperity and stability."
The HKSAR delegation to the Two Sessions said the proposed improvements would not make any change to "One Country, Two Systems," but would strengthen the principle, as well as put an end to the political chaos in Hong Kong and allow local society to focus on economic development, people's livelihood and the SAR's integration into the overall development of the country.
No one cares more about Hong Kong's democracy and continued prosperity and stability than the Central Government of China, Chinese State Councilor and Foreign Minister Wang Yi stated on Sunday, adding that Hong Kong's shift from chaos to stability serves the interests of all parties.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210308005793/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
